1. Home
  2. KGEI vs SPRO Comparison

KGEI vs SPRO Comparison

Compare KGEI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KGEI

Kolibri Global Energy Inc.

HOLD

Current Price

$5.36

Market Cap

191.0M

Sector

N/A

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.85

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KGEI
SPRO
Founded
2008
2013
Country
United States
United States
Employees
N/A
25
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.0M
156.3M
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
KGEI
SPRO
Price
$5.36
$2.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
219.9K
861.4K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
$32.37
N/A
Revenue Next Year
$4.72
$300.00
P/E Ratio
$7.94
N/A
Revenue Growth
N/A
39.24
52 Week Low
$3.35
$1.80
52 Week High
$8.27
$3.09

Technical Indicators

Market Signals
Indicator
KGEI
SPRO
Relative Strength Index (RSI) 47.56 54.76
Support Level $5.07 $2.18
Resistance Level $5.88 $3.07
Average True Range (ATR) 0.30 0.18
MACD -0.03 -0.02
Stochastic Oscillator 42.61 57.50

Price Performance

Historical Comparison
KGEI
SPRO

About KGEI Kolibri Global Energy Inc.

Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: